Prior studies have revealed that the presence of increasing number of polyclonal plasma cells (pPCs) in the bone marrow (BM) are associated with better outcomes in newly diagnosed multiple myeloma (MM) patients. This effect has not been studied in patients with MM at the time of disease relapse. We determined the prognostic value of depletion of pPCs in the BM by 7-color multiparameter flow cytometry in a series of 174 relapsing MM patients. The time to next therapy (TTNT) in those with <5% pPCs was 9.4 months versus 13.9 months in those with 5% pPCs (P 5 .0091). The median overall survival (OS) in those with <5% pPCs was 21.4 months, while the median OS was not reached in those patients with 5% pPCs (P 5 .019). Of the 109 patients with standard risk cytogenetics, the median OS of those with <5% pPCs was 28.4 months, while the median OS was not reached in those with 5% pPCs (P 5 .033). As such, <5% pPCs in the BM appears to have prognostic utility in identifying a subset of relapsing MM patients, even with standard-risk cytogenetics, who have a particularly adverse outcome.
| I N T R O D U C T I O N
With the advent of immunomodulators (IMiDs) and proteasome inhibitors (PIs), as well as the incorporation of high dose chemotherapy followed by autologous stem cell transplantation (ASCT), the survival of patients with MM has greatly improved over the last decade.
1,2 However, MM remains mostly incurable and most patients experience disease relapse with significant variability in terms of clinical features, response to therapy and overall survival (OS) due to the heterogeneous biology of the disease. 3, 4 Several prognostic markers have been studied to identify MM patients with high-risk disease and poor OS, including cytogenetics, gene expression profiling, labeling index or S-phase fraction, circulating clonal plasma cells, and the International Staging System (ISS). 5 In current clinical practice, multiparameter flow cytometry has been increasingly utilized to characterize the plasma cells (PCs) in the BM as normal/polyclonal or malignant/clonal based on their immunophenotypic signatures. 6 The presence of >5% polyclonal PCs (pPCs) in monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) has been associated with a low risk of progression to symptomatic MM. 7 A previous study also demonstrated that the presence of >5% pPCs within the total bone marrow plasma cells (BMPCs) in newly diagnosed MM patients is associated with longer progression-free survival and OS. 8 However, the prognostic utility of quantifying pPCs within the BMPCs in those patients with actively relapsing MM has not been studied to date. This retrospective study identifies the clinical characteristics of patients with actively relapsing MM associated with the presence of bone marrow (BM) pPCs and determines the prognostic value of quantifying the pPCs in the BM. Statistical analyses were performed using JMP 10.0.1 (SAS Institute Inc., Cary NC). Kaplan-Meier analysis was performed to create OS and TTNT curves, and the log-rank test was used to compare the curves. Chi-square and t-tests were used to determine statistical differences in the characteristics between the subgroups of interest. A multivariate analysis was performed using the Cox proportional hazards model to determine hazard ratios to assess the influence of various prognostic factors on OS. Of these patients, 122 (70%) were determined to have <5% pPCs and 52 (30%) were determined to have 5% pPCs (Range: 5%-98%).
| M E T H O D S

| R E S U L T S
The clinical characteristics of the patients in the two groups based on the percentage of pPCs are compared in Table 1 . There were 63 (36%) patients who had received more than 3 lines of prior treatment regimens. Patients with <5% pPCs had a higher median b2-microglobulin
6 mg/L, P 5 .017), median BMPCs (40% vs 10%, P .001), and higher proportion of patient with HR FISH (37% vs 16%, P 5 .008) compared to those patients with 5% pPCs. There were 74 (67%) patients who received 3 or less lines of prior therapy that had <5% pPCs in comparison to 48 (76%) patients who received more than 3 prior lines of therapy that had <5% pPCs (P 5 .229). Immunoparesis of one or more uninvolved immunoglobulins was more likely to be present in the group of patients with <5% pPCs compared with those with 5% pPCs (96% vs. 76%, P 5 .001) (Supporting Information Figure S2 ).
Similarly, immunoparesis of two or more uninvolved immunoglobulins was more likely to be present in the group of patients with <5% pPCs compared with those with 5% pPCs (87% vs. 41%, P < 0.001). The uninvolved free light chain concentration was also more likely to be suppressed to levels below the lower limit of normal in the group of patients with <5% pPCs compared with those with 5% pPCs (51% vs.
22%, P 5 .0004). When evaluating only the patients with standard-risk disease by FISH, those patients with <5% pPCs were more likely to have a b2-microglobulin >5.5 mcg/L (28% vs. 14%; P 5 .250) and a LDH >222 U/L (26% vs. 17%; P 5 .405) at relapse compared to patients with 5% pPCs, though this was not statistically significant.
Adequate treatment data for TTNT was available in 156 of the 174 (90%) relapsing patients, with median TTNT determined to be 4.5 months longer in those with 5% pPCs (13.9 months) compared to those with <5% pPCs (9.4 months) (P 5 .0091) ( Figure 1A ). Median OS was also better in patients with 5% pPCs compared to the patients with <5% pPCs (not reached vs. 21.4 months) (P 5 .019) ( Figure 1B ). There are several limitations to our study, the first being its retrospective nature. Second, the antibody panel utilized by flow cytometry in our study to discriminant between clonal PCs and pPCs is different compared to the recent EuroFlow recommendations established. 19 Thus, prospective validation of our results using the EuroFlow antibody panel to demonstrate the prognostic value of detecting <5% pPCs is needed to assess its ability to be adopted as a standard test among other practicing clinicians. Another limitation of this study was the lack of data on whether patients relapsed while on therapy or within a short period after completing therapy as the former could likely bear worse survival outcomes. Despite the association of <5% pPCs in the BM of patients with relapsed MM and the presence of high risk cytogenetics and elevated b2-microglobulin levels, the presence of <5% pPCs still identifies several more patients with standard risk cytogenetics and normal b2-microglobulin levels who experience poor survival outcomes. Thus, quantification of pPCs in the BM can provide additive prognostic value to clinicians and patients. Future mechanistic studies that can evaluate the biological significance of pPCs in patients with MM are warranted with a specific emphasis on identifying a specific subgroup of patients with a unique biologic signature and prolonged survival that could benefit from specific therapeutic approaches. 
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